Tech Company Financing Transactions
Somite Therapeutics Funding Round
On 5/13/2025, Somite Therapeutics announced Series A funding from Khosla Ventures, Ajinomoto Co and Chan Zuckerberg Initiative.
Transaction Overview
Company Name
Announced On
5/13/2025
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to accelerate key therapeutic programs, including beta cells for type 1 diabetes, articular cartilage for orthopedic applications, satellite cells for muscular diseases, and hematopoietic cells for blood disorders, and further develop the capabilities of its DeltaStem platform.
Company Information
Company Status
Private & Independent
Industry
Artificial Intelligence
Mailing Address
240 Longwood Ave, Building C
Boston, MA 02115
USA
Boston, MA 02115
USA
Phone
Undisclosed
Website
Email Address
Overview
Somite.ai is leveraging big data and AI to introduce novel cell replacement therapies. We're developing a digital twin of the embryo, i.e. a computational model that simulates the real embryo's development and behavior to guide decision-making.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Micha Breakstone
Chief Scientific Officer
Carl Morris
Chief Technical Officer
Jonathan Rosenfeld
Co-Founder
Allon Klein
Co-Founder
Olivier Pourquie
Co-Founder
Cliff Tabin
VP - Bus. Development
Kristy Brown
Browse more venture capital transactions:
Prev: 5/13/2025: Scription venture capital transaction
Next: 5/13/2025: Stylus Medicine venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs